JP6788003B2 - スタチン封入ナノ粒子を含有する機能増強幹細胞を含む炎症性疾患治療用細胞製剤 - Google Patents
スタチン封入ナノ粒子を含有する機能増強幹細胞を含む炎症性疾患治療用細胞製剤 Download PDFInfo
- Publication number
- JP6788003B2 JP6788003B2 JP2018515716A JP2018515716A JP6788003B2 JP 6788003 B2 JP6788003 B2 JP 6788003B2 JP 2018515716 A JP2018515716 A JP 2018515716A JP 2018515716 A JP2018515716 A JP 2018515716A JP 6788003 B2 JP6788003 B2 JP 6788003B2
- Authority
- JP
- Japan
- Prior art keywords
- stem cells
- statin
- nanoparticles
- adipose
- encapsulated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 210000000130 stem cell Anatomy 0.000 title claims description 236
- 239000002105 nanoparticle Substances 0.000 title claims description 217
- 210000004027 cell Anatomy 0.000 title claims description 58
- 208000027866 inflammatory disease Diseases 0.000 title claims description 31
- 238000002360 preparation method Methods 0.000 title claims description 12
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims description 55
- 229920000747 poly(lactic acid) Polymers 0.000 claims description 44
- 239000004626 polylactic acid Substances 0.000 claims description 42
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims description 34
- 206010012289 Dementia Diseases 0.000 claims description 13
- 201000008482 osteoarthritis Diseases 0.000 claims description 12
- 229920000642 polymer Polymers 0.000 claims description 12
- 208000028389 Nerve injury Diseases 0.000 claims description 10
- 238000013508 migration Methods 0.000 claims description 10
- 230000005012 migration Effects 0.000 claims description 10
- 230000008764 nerve damage Effects 0.000 claims description 10
- 208000029523 Interstitial Lung disease Diseases 0.000 claims description 9
- 206010039710 Scleroderma Diseases 0.000 claims description 9
- 201000000980 schizophrenia Diseases 0.000 claims description 8
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 5
- 238000001990 intravenous administration Methods 0.000 claims description 5
- 230000002062 proliferating effect Effects 0.000 claims description 5
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Natural products OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims description 4
- 229920001577 copolymer Polymers 0.000 claims description 4
- 238000013268 sustained release Methods 0.000 claims 1
- 239000012730 sustained-release form Substances 0.000 claims 1
- 238000011200 topical administration Methods 0.000 claims 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 60
- 241000699670 Mus sp. Species 0.000 description 57
- 101100102907 Mus musculus Wdtc1 gene Proteins 0.000 description 48
- 239000008363 phosphate buffer Substances 0.000 description 48
- 238000000034 method Methods 0.000 description 34
- 238000010172 mouse model Methods 0.000 description 25
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 23
- 238000004458 analytical method Methods 0.000 description 21
- 239000002904 solvent Substances 0.000 description 21
- 239000002245 particle Substances 0.000 description 20
- 230000001225 therapeutic effect Effects 0.000 description 17
- 239000000243 solution Substances 0.000 description 16
- 210000001519 tissue Anatomy 0.000 description 16
- 210000000577 adipose tissue Anatomy 0.000 description 15
- 239000003925 fat Substances 0.000 description 15
- 230000006870 function Effects 0.000 description 15
- 230000000694 effects Effects 0.000 description 14
- 238000012360 testing method Methods 0.000 description 14
- 238000005259 measurement Methods 0.000 description 13
- 108010006654 Bleomycin Proteins 0.000 description 12
- 230000003110 anti-inflammatory effect Effects 0.000 description 12
- 229960001561 bleomycin Drugs 0.000 description 12
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 230000006399 behavior Effects 0.000 description 11
- 208000004232 Enteritis Diseases 0.000 description 10
- 206010061218 Inflammation Diseases 0.000 description 10
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 10
- 230000004054 inflammatory process Effects 0.000 description 10
- 210000002429 large intestine Anatomy 0.000 description 10
- 239000002609 medium Substances 0.000 description 10
- 229960002855 simvastatin Drugs 0.000 description 10
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 10
- TVZRAEYQIKYCPH-UHFFFAOYSA-N 3-(trimethylsilyl)propane-1-sulfonic acid Chemical compound C[Si](C)(C)CCCS(O)(=O)=O TVZRAEYQIKYCPH-UHFFFAOYSA-N 0.000 description 9
- 210000003491 skin Anatomy 0.000 description 9
- 208000024891 symptom Diseases 0.000 description 9
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 8
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 7
- 210000000845 cartilage Anatomy 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 210000004969 inflammatory cell Anatomy 0.000 description 7
- 210000004072 lung Anatomy 0.000 description 7
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 6
- 210000001188 articular cartilage Anatomy 0.000 description 6
- 239000000839 emulsion Substances 0.000 description 6
- 239000001963 growth medium Substances 0.000 description 6
- 230000008595 infiltration Effects 0.000 description 6
- 238000001764 infiltration Methods 0.000 description 6
- OARRHUQTFTUEOS-UHFFFAOYSA-N safranin Chemical compound [Cl-].C=12C=C(N)C(C)=CC2=NC2=CC(C)=C(N)C=C2[N+]=1C1=CC=CC=C1 OARRHUQTFTUEOS-UHFFFAOYSA-N 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 230000037396 body weight Effects 0.000 description 5
- 238000009792 diffusion process Methods 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 230000002708 enhancing effect Effects 0.000 description 5
- 230000014509 gene expression Effects 0.000 description 5
- 230000001506 immunosuppresive effect Effects 0.000 description 5
- 210000000936 intestine Anatomy 0.000 description 5
- 238000001361 intraarterial administration Methods 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 238000012549 training Methods 0.000 description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- 108060005980 Collagenase Proteins 0.000 description 4
- 102000029816 Collagenase Human genes 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 4
- 239000012981 Hank's balanced salt solution Substances 0.000 description 4
- 108050003558 Interleukin-17 Proteins 0.000 description 4
- 108090001005 Interleukin-6 Proteins 0.000 description 4
- 229930040373 Paraformaldehyde Natural products 0.000 description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 4
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 4
- 230000003915 cell function Effects 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 229960002424 collagenase Drugs 0.000 description 4
- 210000004207 dermis Anatomy 0.000 description 4
- 210000000629 knee joint Anatomy 0.000 description 4
- 239000004310 lactic acid Substances 0.000 description 4
- 235000014655 lactic acid Nutrition 0.000 description 4
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 230000007659 motor function Effects 0.000 description 4
- 229920002866 paraformaldehyde Polymers 0.000 description 4
- 239000008188 pellet Substances 0.000 description 4
- 210000003497 sciatic nerve Anatomy 0.000 description 4
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 3
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 3
- 230000001464 adherent effect Effects 0.000 description 3
- 210000001264 anterior cruciate ligament Anatomy 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000001185 bone marrow Anatomy 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 210000003127 knee Anatomy 0.000 description 3
- 210000002414 leg Anatomy 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 230000001172 regenerating effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000007440 spherical crystallization Methods 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 210000004003 subcutaneous fat Anatomy 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 210000002303 tibia Anatomy 0.000 description 3
- 210000004353 tibial menisci Anatomy 0.000 description 3
- CABVTRNMFUVUDM-VRHQGPGLSA-N (3S)-3-hydroxy-3-methylglutaryl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C[C@@](O)(CC(O)=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 CABVTRNMFUVUDM-VRHQGPGLSA-N 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 2
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 2
- 208000011231 Crohn disease Diseases 0.000 description 2
- 208000035150 Hypercholesterolemia Diseases 0.000 description 2
- 108010052014 Liberase Proteins 0.000 description 2
- 101100460719 Mus musculus Noto gene Proteins 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 238000000149 argon plasma sintering Methods 0.000 description 2
- 229960005370 atorvastatin Drugs 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 230000035622 drinking Effects 0.000 description 2
- 210000001671 embryonic stem cell Anatomy 0.000 description 2
- 208000010227 enterocolitis Diseases 0.000 description 2
- 238000006911 enzymatic reaction Methods 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000005484 gravity Effects 0.000 description 2
- 230000002949 hemolytic effect Effects 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 210000004263 induced pluripotent stem cell Anatomy 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 210000005087 mononuclear cell Anatomy 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- -1 pH adjusters Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 208000002815 pulmonary hypertension Diseases 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 210000004876 tela submucosa Anatomy 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 1
- FJLGEFLZQAZZCD-MCBHFWOFSA-N (3R,5S)-fluvastatin Chemical compound C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 FJLGEFLZQAZZCD-MCBHFWOFSA-N 0.000 description 1
- XNCSCQSQSGDGES-UHFFFAOYSA-N 2-[2-[bis(carboxymethyl)amino]propyl-(carboxymethyl)amino]acetic acid Chemical compound OC(=O)CN(CC(O)=O)C(C)CN(CC(O)=O)CC(O)=O XNCSCQSQSGDGES-UHFFFAOYSA-N 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 238000011729 BALB/c nude mouse Methods 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 206010018367 Glomerulonephritis chronic Diseases 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 102000004286 Hydroxymethylglutaryl CoA Reductases Human genes 0.000 description 1
- 108090000895 Hydroxymethylglutaryl CoA Reductases Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 206010060820 Joint injury Diseases 0.000 description 1
- 238000000134 MTT assay Methods 0.000 description 1
- 231100000002 MTT assay Toxicity 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 208000034530 PLAA-associated neurodevelopmental disease Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 description 1
- AJLFOPYRIVGYMJ-UHFFFAOYSA-N SJ000287055 Natural products C12C(OC(=O)C(C)CC)CCC=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 AJLFOPYRIVGYMJ-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 238000002266 amputation Methods 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 210000001217 buttock Anatomy 0.000 description 1
- 230000007211 cardiovascular event Effects 0.000 description 1
- 210000001168 carotid artery common Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 201000005795 chronic inflammatory demyelinating polyneuritis Diseases 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 230000009266 disease activity Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 210000000454 fifth toe Anatomy 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 229960003765 fluvastatin Drugs 0.000 description 1
- 210000000455 fourth toe Anatomy 0.000 description 1
- 230000035929 gnawing Effects 0.000 description 1
- 210000004013 groin Anatomy 0.000 description 1
- 210000001255 hallux Anatomy 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 230000003832 immune regulation Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 210000001503 joint Anatomy 0.000 description 1
- 238000002350 laparotomy Methods 0.000 description 1
- 201000010901 lateral sclerosis Diseases 0.000 description 1
- 238000007443 liposuction Methods 0.000 description 1
- 229960004844 lovastatin Drugs 0.000 description 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 229950009116 mevastatin Drugs 0.000 description 1
- AJLFOPYRIVGYMJ-INTXDZFKSA-N mevastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=CCC[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 AJLFOPYRIVGYMJ-INTXDZFKSA-N 0.000 description 1
- BOZILQFLQYBIIY-UHFFFAOYSA-N mevastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CCC=C21 BOZILQFLQYBIIY-UHFFFAOYSA-N 0.000 description 1
- 230000001617 migratory effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 208000005264 motor neuron disease Diseases 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 210000001778 pluripotent stem cell Anatomy 0.000 description 1
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 229960002965 pravastatin Drugs 0.000 description 1
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 229960000672 rosuvastatin Drugs 0.000 description 1
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 description 1
- 230000000698 schizophrenic effect Effects 0.000 description 1
- 210000000453 second toe Anatomy 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 210000001988 somatic stem cell Anatomy 0.000 description 1
- 208000020431 spinal cord injury Diseases 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000012128 staining reagent Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Landscapes
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Description
・個数平均粒径の上限は、1000nm未満、好ましくは約600nm以下(より好ましくは600nm以下)、更に好ましくは約400nm以下(より好ましくは400nm以下)である。
・個数平均粒径の下限は、約100nm以上(より好ましくは100nm以上)、好ましくは約200nm以上(より好ましくは200nm以上)である。
例えば、スタチン封入ナノ粒子の個数平均粒径は、光散乱法で測定したときに、1000nm未満、好ましくは約100nm〜約600nm(より好ましくは100nm〜600nm)、更に好ましくは約200nm〜約400nm(より好ましくは200nm〜400nm)となる。
本発明において、スタチン封入ナノ粒子は、上述の個数平均粒径を満たすように加工することができる方法であればいかなる方法によっても製造されることができるが、好ましくは球形晶析法を使用して製造される。球形晶析法は、化合物合成の最終プロセスにおける結晶の生成・成長プロセスを制御することで、球状の結晶粒子を設計し、その物性を直接制御して加工することができる方法として周知である。この球形晶析法の一つに、周知のエマルジョン溶媒拡散法(ESD法)がある。
1 正常組織
2 粘膜・粘膜下層に少量の炎症性細胞浸潤
3 粘膜・粘膜下層に多量の炎症性細胞浸潤
4 クリプト膿瘍の存在と粘膜全層に多数の炎症性細胞浸潤
5 炎症性細胞浸潤を伴った粘膜組織のびらん・潰瘍・壊死。
SFI=-38.3×(EPL-NPL)/NPL+109.5×(ETS-NTS)/NTS+13.3×(EIT-NIT)/NIT-8.8
各群におけるSFIの測定結果を図16のグラフに示す。図16に示すように、PBSのみを投与したマウスと比較して、スタチンが非封入のナノ粒子を含むマウス脂肪由来幹細胞を投与したマウス(AdSC)では、SFIが高くなっており、運動機能が回復したことが認められる。さらに、スタチン封入ナノ粒子を含むマウス脂肪由来幹細胞を投与したマウス(Sim−AdSC)では、SFIがより高くなっており、より運動機能が回復したことが認められる。これらの結果から、スタチン封入ナノ粒子を含む脂肪由来幹細胞によって、神経損傷の症状を改善できることが示唆される。
Claims (3)
- スタチン封入ナノ粒子を含有する機能増強幹細胞を含む、炎症性疾患を治療するための細胞製剤であって、
前記スタチン封入ナノ粒子は、スタチンが生体吸収性ポリマーを含むナノ粒子に封入されてなるものであり、
前記幹細胞は脂肪由来幹細胞であり、
前記機能増強幹細胞は、遊走能又は増殖能が増強されているとともに、スタチンを徐放する機能を有しており、
前記炎症性疾患は、炎症性腸疾患、間質性肺炎、強皮症、神経損傷、統合失調症、変形性関節症または認知症であることを特長とする、細胞製剤。 - 前記生体吸収性ポリマーが、ポリ乳酸重合体(PLA)又はポリ乳酸グリコール酸共重合体(PLGA)である、請求項1に記載の細胞製剤。
- 動脈投与用、静脈投与用または局所投与用である、請求項1または2に記載の細胞製剤。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2016166299 | 2016-08-26 | ||
JP2016166299 | 2016-08-26 | ||
PCT/JP2017/016858 WO2017191808A1 (ja) | 2016-05-06 | 2017-04-27 | 炎症性疾患治療用幹細胞の機能増強用スタチン封入ナノ粒子製剤、及びそれを含有する炎症性疾患治療用機能増強幹細胞 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPWO2017191808A1 JPWO2017191808A1 (ja) | 2019-06-27 |
JP6788003B2 true JP6788003B2 (ja) | 2020-11-18 |
Family
ID=67061518
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018515716A Expired - Fee Related JP6788003B2 (ja) | 2016-08-26 | 2017-04-27 | スタチン封入ナノ粒子を含有する機能増強幹細胞を含む炎症性疾患治療用細胞製剤 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP6788003B2 (ja) |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2532595T3 (es) * | 2006-08-30 | 2015-03-30 | Kyushu University, National University Corporation | Composición farmacéutica que contiene una nanopartícula de estatina encapsulada |
ES2479544T1 (es) * | 2011-01-12 | 2014-08-20 | Tigenix, S.A.U. | Células madre mesenquimales derivadas de tejido adiposo para administración intralinfática en enfermedades autoimmunes e inflamatorias |
JP5993113B2 (ja) * | 2011-01-31 | 2016-09-14 | 株式会社 バイオミメティクスシンパシーズ | アルツハイマー病治療に向けたヒト脂肪組織由来間葉系幹細胞 |
CN107206084B (zh) * | 2014-11-10 | 2021-05-14 | 伊井正明 | 用于增强干细胞功能的内含抑制素纳米粒子制剂以及含有其的功能增强干细胞及其制备方法 |
-
2017
- 2017-04-27 JP JP2018515716A patent/JP6788003B2/ja not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
JPWO2017191808A1 (ja) | 2019-06-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6560381B2 (ja) | 脂肪組織または胎盤組織に由来する接着性細胞および治療におけるその使用 | |
Saulnier et al. | Intra-articular administration of xenogeneic neonatal mesenchymal stromal cells early after meniscal injury down-regulates metalloproteinase gene expression in synovium and prevents cartilage degradation in a rabbit model of osteoarthritis | |
US20210038725A1 (en) | Statin-containing nanoparticle preparation for enhancing function of stem cells for treating inflammatory disease, and functionally enhanced stem cells containing same for treating inflammatory disease | |
EP2162141B1 (en) | Composition for treating ischemic limb disease comprising stem cells derived from adipose tissue | |
US20120201791A1 (en) | Methods of treating diseases or conditions using mesenchymal stem cells | |
JP6110578B2 (ja) | 幹細胞機能増強用スタチン封入ナノ粒子製剤、並びにそれを含有する機能増強幹細胞及びその製造方法 | |
CN104105493A (zh) | 哺乳动物胎儿肺细胞以及其治疗用途 | |
WO2017144552A1 (en) | Pharmaceutical or veterinary cell compositions comprising mesenchymal stromal cells (mscs) and dimethyl sulfoxide (dmso) | |
JP6788003B2 (ja) | スタチン封入ナノ粒子を含有する機能増強幹細胞を含む炎症性疾患治療用細胞製剤 | |
JP6929346B2 (ja) | 軟骨無細胞破砕物及び幹細胞を含む軟骨分化促進用複合体及びその用途 | |
WO2013168402A1 (ja) | デキストラン含有肺塞栓形成予防用哺乳動物細胞懸濁液 | |
Wang et al. | Bone marrow stromal cells sorted by semiconducting polymer nanodots for bone repair | |
WO2019216437A1 (ja) | スタチン封入ナノ粒子製剤、それを含有する歯髄由来幹細胞及びそれを含む細胞製剤 | |
Çekiç et al. | Impact of injectable chitosan cryogel microspherescaffolds on differentiation and proliferation of adiposederived mesenchymal stem cells into fat cells | |
US20230218572A1 (en) | Compositions and methods for improved mesenchymal stem cell therapy | |
Lokman | Imaging the injured beating heart intravitally and the vasculoprotection afforded by haematopoietic stem cells in myocardial ischaemia/reperfusion injury | |
Harman | Stem cell veterinary medicines: a practical approach | |
Millan | Formation of Engineered Microtissues by Schiff Base Crosslinking |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A527 Effective date: 20181031 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20181031 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20191008 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20191122 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200116 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200512 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200707 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20201006 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20201029 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6788003 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
LAPS | Cancellation because of no payment of annual fees |